ICON Selected by the FDA to Validate Patient-Reported Outcome Endpoints for Antibacterial Drug Trials Read more
CTT Pharmaceutical Holdings and CanniMed Therapeutics Inc. Complete Exclusive Canadian Licensing Agreement Read more
Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery Read more
Jazz enrolls first patient in JZP-110’s phase 2 trial for excessive sleepiness in PD patients Read more